Clinical Trials
Sep 15, 2026 · 1 min read · 59,001 views
Chinese startup begins first trial of in vivo CRISPR therapy for blood disease
D
Daniel Park
Editorial · Sep 15, 2026
A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field's most competitive races. YolTech Therapeutics announced Monday that it started
← Previous
Ayisha Sharma - Endpoints News
Next →
Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial
